Q1. Do you see any other challenges with the information to be provided by NFC- to FC which should be addressed? In particular, do you foresee any challenges related to the FC being aware of the changes in the NFC status?

Q2. Do you agree with the proposals set out in this section? If not, please clarify your concerns and propose alternative solutions.

Q3. Do you need any further clarifications regarding the scenario in which the FC and NFC- report to two different TRs?

Q4. Are there any other aspects related to the allocation of responsibility of reporting that should be covered in the technical standards? If so, please clarify which and how they should be addressed.

Q5. Do you see any other challenges with the information by NFC- to FC of their decision to perform the reporting of OTC derivatives which should be addressed?

Q6. Do you agree with the proposals set out in this section? If not, please clarify your concerns and propose alternative solutions.

Q7. Do you see any issues with the approach outlined above? Do you see any other challenges with the delegation of reporting which should be addressed?

Q8. Which errors or omissions in reporting should, in your view, be notified to the competent authorities? Do you see any major challenges with such notifications to be provided to the competent authorities? If yes, please clarify your concerns.